Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
about
Quantitative Imaging Biomarkers of NAFLDIncreased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALDNonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.Diagnosis of non-alcoholic fatty liver disease (NAFLD).Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.NAFLD and diabetes mellitus.Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.Estimating of hepatic fat amount using MRI proton density fat fraction in a real practice setting.Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.Current and future pharmacological therapies for NAFLD/NASH.Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan.Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease.NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older PatientsUtility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
P2860
Q26768664-5DAAA5D7-9E7E-41F4-AEBF-610170D2C101Q30238749-10FF72DD-C4BF-4F79-8AC9-31724D72D8C3Q30364476-B3E5FCDF-84B0-4755-A029-B3133A0191FBQ33852213-7C0EB68C-E43D-4A6D-BE23-ADC11B761A24Q33855157-BC28F5C7-0198-4E36-992D-9DB9E7A40239Q35932326-DBE5555A-947E-4339-9B4B-0469D06A06A7Q37173770-F41E8E9D-048D-4205-9757-FB9E5208F3D7Q38811383-8A7472EB-EF83-4B77-9586-64604C9EB685Q38833207-1413B5B3-3BF9-4B1A-BBDA-ACB29C7D9DE9Q38867829-660AD971-10F4-483A-9B49-124A12F33EDDQ38978347-F5BC2C99-B5B4-49BD-A7BD-15A08B25BF7BQ39030264-40FC8BC7-973A-4F3A-AEEF-B6713E97C03CQ39170830-6E695BCA-B35F-44A2-A14B-EB9B91AD3FA9Q40039094-4826D10F-3046-498D-8235-80209DBB8401Q40079847-AF7C0464-B0A8-4C87-9A6F-E1405E406BE1Q40444861-A5BAFE8A-FCB2-4274-B0EA-C8B3455C7F06Q40766803-863BFDD2-545E-40F2-A0EB-A1E773880727Q42367659-920A152A-3664-44DA-A37F-8760352F5A71Q45942296-77A5761E-C924-4EDA-9C12-2890CAEFC8BAQ46220517-F229491A-0FB9-4747-9751-3D9E8F465743Q47228561-D5D6BF6C-E294-4221-9DB7-9955335AB79FQ47778507-11177DE4-9231-48FB-9CCA-7FB1C16A79C7Q47849653-73C69B73-8639-49D3-AD61-3EA98154AC54Q48170286-0AA457DA-F6E0-4AD5-A0BE-1B238FBEC22AQ48296765-556ED35C-EF4E-4521-83BC-7BB7BD9D22B2Q54232638-A37B8D8A-8F32-4744-B955-4AAD0815BB95Q57818992-95BF51B4-92D7-48F0-90C3-E6E00E434BF0Q58760217-84973684-4E8A-4555-8E32-1BFF7B7DD86B
P2860
Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Non-invasive screening of diab ...... anced fibrosis by MRI and MRE.
@ast
Non-invasive screening of diab ...... anced fibrosis by MRI and MRE.
@en
type
label
Non-invasive screening of diab ...... anced fibrosis by MRI and MRE.
@ast
Non-invasive screening of diab ...... anced fibrosis by MRI and MRE.
@en
prefLabel
Non-invasive screening of diab ...... anced fibrosis by MRI and MRE.
@ast
Non-invasive screening of diab ...... anced fibrosis by MRI and MRE.
@en
P2093
P2860
P356
P1476
Non-invasive screening of diab ...... anced fibrosis by MRI and MRE.
@en
P2093
H Hofflich
I Doycheva
R Bettencourt
P2860
P356
10.1111/APT.13405
P407
P577
2015-09-15T00:00:00Z